Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481293 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ABL1MCL1 | |
| SCHEMBL3720560 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ABL1MCL1 | |
| SCHEMBL30718642 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ABL1MCL1 | |
| SCHEMBL14684657 | 0.84 | MAP3K5 (0.42) | KDM4EALDH1A1SMN1; SMN2ABL1MCL1 | |
| SCHEMBL31165703 | 0.80 | LCK (0.55) | KDM4EALDH1A1ABL1GSK3ACDK9 | |
| SCHEMBL3207019 | 0.79 | KDM4E (0.49) | KDM4EALDH1A1ABL1ASPHKDM8 | |
| SCHEMBL6099196 | 0.79 | CYP2A6 (0.45) | KDM4EALDH1A1ABL1ASPHKDM8 | |
| SCHEMBL6101082 | 0.79 | KMO (0.46) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL31055620 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL4670841 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709479-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| WO-2024233563-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2019201296-A1 | PYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | 南京明德新药研发有限公司 | 2019-10-24 | — | — | WO | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180362501-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218042-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | KDM4E 2139/4885ALDH1A1 1882/4885SMN1; SMN2 2276/4885 |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | KDM4E 874/4885ALDH1A1 3352/4885SMN1; SMN2 551/4885 |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | KDM4E 3546/4885ALDH1A1 1195/4885SMN1; SMN2 3272/4885 |
| US-20180362501-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | BAD, CASP1, BAX | KDM4E 2139/4885ALDH1A1 1882/4885SMN1; SMN2 2276/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 4173/4885ALDH1A1 2379/4885SMN1; SMN2 2486/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | KDM4E 751/4885ALDH1A1 4576/4885SMN1; SMN2 2723/4885 |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | KDM4E 1293/4885ALDH1A1 1247/4885SMN1; SMN2 1597/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | KDM4E 3546/4885ALDH1A1 1195/4885SMN1; SMN2 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.